45
Astellas
4503.T·TSETokyo JPFounded 200514,000 employees
Large CappharmaPublicOncologyUrologyRare Disease
Platform: Gene & ADC
Market Cap
$22B
All Drugs
7
Clinical Trials
14
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (4503.T)
Loading 4503.T stock data...
Drug Pipeline (7 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 450-8514 | 450-8514 | Phase 3 | 4 | RET | PsANB | ||
| 450-5704 | 450-5704 | Phase 2/3 | 2 | PRMT5 | ThymomaGIST | ||
| Mavuvorutinib | 450-5746 | Phase 1/2 | 2 | CD47 | UCRA | ||
| Pemilemzoparlimab | 450-4043 | Phase 1/2 | 2 | MALT1 | TTR Amyloidosis | ||
| Nirabrutinib | 450-8450 | Phase 2 | 2 | DLL3 | AS | ||
| Adagrafutibatinib | 450-7598 | Phase 2 | 1 | CDK4/6 | UCDMD | ||
| 450-8195 | 450-8195 | NDA/BLA | 1 | TROP-2 | MSBCC |
SEC Filings & Financial Documents
SEC filings are not available for TSE-listed companies.
Astellas trades on TSE (JP). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (11)